Clinical trials have shown that anti-CD22 CAR-T cell therapy is highly effective in patients with R/R B-ALL and R/R DLBCL who have not responded to previous anti-CD19 CAR-T cell therapy (34–36). Here, CD19 is linked to diffuse large B-cell lymphoma.